Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 555Lymphoma 447Precursor Cell Lymphoblastic Leukemia-Lymphoma 413Lymphoma, Large B-Cell, Diffuse 348Leukemia 346Multiple Myeloma 336Lymphoma, Non-Hodgkin 317Leukemia, Myeloid, Acute 289Leukemia, Lymphocytic, Chronic, B-Cell 286Lymphoma, Follicular 241Burkitt Lymphoma 217Myelodysplastic Syndromes 211Lymphoma, Mantle-Cell 202Hodgkin Disease 193Recurrence 155Lymphoma, B-Cell, Marginal Zone 142Melanoma 136Lymphoma, Large-Cell, Immunoblastic 116Neoplasms 109Lymphoma, B-Cell 103Neuroblastoma 101Neoplasms, Plasma Cell 99Ovarian Neoplasms 96Triple Negative Breast Neoplasms 94Leukemia, Myelogenous, Chronic, BCR-ABL Positive 91Myeloproliferative Disorders 87Hematologic Neoplasms 87Leukemia, Myeloid, Chronic-Phase 83Leukemia, Myeloid, Accelerated Phase 80Leukemia, Myelomonocytic, Chronic 78

Interventions

Standard of Care 4Practice Guidelines as Topic 4Methods 4Interviews as Topic 4Educational Status 4Early Intervention, Educational 4Specimen Handling 2Exercise Test 2Counseling 2Behavior Therapy 2fludarabine 1Whole-Body Irradiation 1Watchful Waiting 1Telemedicine 1Tacrolimus 1Stem Cell Transplantation 1Rituximab 1Psychotherapy 1Positron-Emission Tomography 1Palliative Care 1Observation 1Mycophenolic Acid 1Music Therapy 1Mindfulness-Based Stress Reduction 1Mindfulness 1Melphalan 1Liquid Biopsy 1Health Promotion 1Granulocyte Colony-Stimulating Factor 1Geriatric Assessment 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematopoietic and Lymphoid System Neoplasm × Cyclophosphamide × Clear all
NCT04022239 2026-01-12

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
25 enrolled

Hematopoietic and Lymphoid System Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡